Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 12/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21947986 | 0.87 | TYK2 (0.46) | TYK2TRPA1KDM4EALDH1A1HPGD | |
| SCHEMBL21948034 | 0.84 | TYK2 (0.48) | TYK2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL20697405 | 0.84 | TYK2 (0.43) | TYK2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL20689398 | 0.84 | TYK2 (0.43) | TYK2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL21947992 | 0.82 | TYK2 (0.43) | TYK2TRPA1 | |
| SCHEMBL22498188 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL30612395 | 0.80 | KDM4E (0.52) | TYK2KDM4EALDH1A1GAAHPGD | |
| Hydrochloric Acid SCHEMBL11452778 | 0.78 | KDM4E (0.51) | TYK2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL27354751 | 0.78 | PARP1 (0.39) | TYK2PARP1PARP2 | |
| SCHEMBL20594635 | 0.78 | KDM4E (0.42) | TYK2KDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885TRPA1 4793/4885KDM4E 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.